COMPANY WORKBOOK · PODD
Insulet Corporation
Healthcare & Life Sciences · Medical Devices
$146.51-6.16%
51/100
INTERACTIVE PRICE CHART
Trend and moving averages
RELATIVE PERFORMANCE
PODD versus SPY and SMH
Indexed to 100
Cross-sectional ranking
Scores are percentile-ranked against the current Young Bull universe and stored by date in PostgreSQL.
Healthcare & Life Sciences
This company is available as a market-data workbook. Young Bull has not added a manual investment thesis for it yet.
MODEL READ
Overall score: 51.3. Last ranked 2026-11-07.
QUARTERLY FUNDAMENTALS
Revenue and earnings power
TRAILING P/E23.94
PRICE / SALES3.19
EV / EBITDA15.31
BOOK VALUEN/A
GROSS MARGIN71.9%
PROFIT MARGIN13.4%
RETURN ON EQUITY28.9%
FREE CASH FLOW113.51M
What it does
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PRIMARY SOURCES